DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for primary hyperparathyroidism — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePrimary hyperparathyroidism maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedCinacalcetApproved drug
Structures already discussed alongside primary hyperparathyroidism in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Human calcium-sensing receptor bound — Cinacalcet has a real, experimentally solved structure in complex with this target (PDB 8WPG, 2.7 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet yp4drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8WPG · 2.7 Å · ligand Cinacalcet (YP4). Experimental structure, not a prediction.
What the evidence adds up to
A 2017 systematic review of medical management for primary hyperparathyroidism analysed 54 studies and calculated weighted mean changes in serum total calcium for several drugs. Pamidronate reduced calcium by 0.31 ± 0.034 mmol/l, alendronate by 0.07 ± 0.05 mmol/l, clodronate by 0.20 ± 0.040 mmol/l, mixed bisphosphonates by 0.16 ± 0.049 mmol/l, and cinacalcet by 0.37 ± 0.013 mmol/l. The meta-regression showed that the calcium-lowering effect of bisphosphonates decreased significantly over time (coefficient -0.049 ± 0.023, p = 0.035), whereas cinacalcet’s effect was sustained. Bisphosphonates improved bone mineral density; cinacalcet did not. The review noted that combining resorptive agents with calcimimetics might be rewarding but called for more studies.
Parathyroid carcinoma accounts for less than 1% of primary hyperparathyroidism cases, as reported in a 2014 case report of a 29-year-old man whose first sign was a pathologic fracture after a trivial fall. The carcinoma was not diagnosed before surgery; final pathology showed a focally positive margin at the site of tracheal invasion. The authors stated that the initial operation offers the best chance for cure and that preoperative staging is usually not feasible.
A 2004 review of genetics described primary hyperparathyroidism as a genetically heterogeneous disease that usually occurs sporadically but can also appear in familial forms. Several responsible genes have been identified, and mutational analysis allows early identification of asymptomatic gene carriers. The review suggested that the molecular mechanisms of parathyroid tumorigenesis could become targets for new therapies, but no such therapies are described in the abstracts.
Two 2025 book chapters (Indications for treatment and Treatment modalities) note that the choice of therapy depends on disease severity, patient circumstances, and risk-benefit assessment of surgery, local destruction, or drugs. They do not provide new trial data. A 1976 paper on changing concepts of parathyroid pathology offers no contemporary evidence. What remains missing are adequately powered randomised trials comparing drug combinations, prospective studies that stratify patients by genetic subtype or disease severity, and funding for long-term outcome studies that go beyond surrogate endpoints like serum calcium and bone density.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in Endocrinology · 2017 · 45 citations · open access
Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review
AbstractIntroduction: Primary hyperparathyroidism is increasingly an asymptomatic disease at diagnosis, but the recognized guidelines for management are based on evidence obtained from studies on patients with symptomatic disease, and surgery is not always indicated. Other patients are unable to undergo surgery, and thus a medical treatment is warranted. This systematic review provides an overview of the existing literature on contemporary pharmaceutical options available for the medical management of primary hyperparathyroidism. Methods: Databases of medical literature were searched for articles including terms for primary hyperparathyroidism and each of the included drugs. Data on s-calcium, PTH, bone turnover markers, bone mass density and hard endpoints were extracted and tabulated, and level of evidence was determined. Changes in s-calcium were estimated and a meta-regression analysis was performed. Results: 1999 articles were screened for eligibility and 54 were included in the review. Weighted mean changes calculated for each drug in s-total calcium (mean change from baseline ± SEM) were: Pamidronate:(0.31 ± 0.034 mmol/l); Alendronate: (0.07 ± 0.05 mmol/l); Clodronate: (0.20±0.040 mmol/l); Mixed bisphosphonates: (0.16 ± 0.049 mmol/l); and Cinacalcet: (0.37 ± 0.013 mmol/l). The meta-analysis revealed a significant decrease of effect on s-calcium with time for the bisphosphonates (Coef. -0.049±0.023, p=0.035), while cinacalcet proved to maintain its effect on s-calcium over time. Bisphosphonates improved BMD while cinacalcet had no effect. Discussion: The included studies demonstrate advantages and drawbacks of the available pharmaceutical options that can prove helpful in the clinical setting. The great variation in how primary hyperparathyroidism is manifested requires that management should rely on an individual evaluation when counseling patients. Combining resorptive agents with calcimimetics could prove rewarding, but more studies are warranted.
AbstractPrimary hyperparathyroidism, a genetically heterogeneous disease, usually occurs as a sporadic disorder due to the presence of parathyroid adenoma/s, hyperplasia or, rarely, carcinoma. In the last decades familial forms of primary hyperparathyroidism have been described. Recognizing such forms is essential for a correct clinical management of affected individual subjects and families. In fact, primary hyperparathyroidism may be the typical feature of familial syndrome or alternatively only an associated disorder within the context of a more complex syndromic picture. Several responsible genes have been so far identified, making their mutational analysis possible, which provides not only early identification of asymptomatic gene carriers, but could also add new important knowledge of the molecular mechanisms underlying parathyroid tumorigenesis. Such mechanisms could, in the near future, become an ideal target for new therapeutic strategies of primary hyperparathyroidism.
Annales d Endocrinologie · 2025 · 6 citations · open access
Chapter 9: Indications for the treatment of primary hyperparathyroidism
AbstractThe choice of therapeutic method for the management of primary hyperparathyroidism depends on the severity of the disease and its complications at the time of diagnosis, the specific situation of each patient and his/her natural history, and assessment of the risk/benefit ratio for each method (surgery, local destruction or drugs). This chapter summarizes the indications for the treatment of primary hyperparathyroidism, based on the international literature available as of December 31st, 2023.
Annales d Endocrinologie · 2025 · 6 citations · open access
Chapter 11: Treatment modalities
AbstractTreatment modalities for primary hyperparathyroidism must take account of the expected benefits and risks of each treatment envisaged, before choosing the definitive option to be proposed to the patient. In this section, a Foreword puts in perspective the difficulties involved in choosing the criteria for a particular treatment method. Treatments are then considered one after the other: surgery, local destruction and medical management. This section does not consider therapeutic indications, which are dealt with in a section 9.
Parathyroid carcinoma presenting with pathologic fracture: Case report and review of the literature
AbstractBACKGROUND: Parathyroid carcinoma is a rare neoplasm representing <1% of primary hyperparathyroidism cases. It is often not diagnosed until surgical exploration as a preoperative diagnosis is often not possible. Thus, preoperative staging for most patients is not feasible and this may compromise the treatment strategy. METHODS AND RESULTS: We report a case of a 29-year-old man presenting with avulsion fracture of the right elbow after a trivial fall. Neck exploration revealed an enlarged left lobe focally adherent to the larynx and trachea. Final pathology revealed parathyroid carcinoma with focally positive margin at the site of tracheal invasion. CONCLUSION: Parathyroid carcinoma is a rare cause of primary hyperparathyroidism. The etiology of parathyroid carcinoma is usually obscured, and the initial operation offers the best chance for cure.
Changing Concepts of Parathyroid Pathology in Primary Hyperparathyroidism
AbstractChanging Concepts of Parathyroid Pathology in Primary Hyperparathyroidism Get access John M. Passmann, M.D. John M. Passmann, M.D. Pathologist, Grant Hospital, Chicago. Search for other works by this author on: Oxford Academic PubMed Google Scholar Laboratory Medicine, Volume 7, Issue 3, 1 March 1976, Pages 7–10, https://doi.org/10.1093/labmed/7.3.7 Published: 01 March 1976
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
